Pertuzumab protects the achilles' heel of trastuzumab--emtansine.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 24240115.
- Also identified by DOI 10.1158/1078-0432.CCR-13-2626.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Trastuzumab emtansine (T-DM1) represents a significant advancement in the treatment of HER2(+) breast cancers. Its clinical efficacy however will be limited by the development of therapeutic resistance. In this report, the HER3 ligand neuregulin is shown to mediate T-DM1 resistance, which was overcome by administration of pertuzumab, a steric inhibitor of HER2 dimerization.
Medical subject headings
- Antibodies, Monoclonal, Humanized
- Breast Neoplasms
- Neuregulins
- Erb-b2 Receptor Tyrosine Kinases